These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35770768)

  • 1. Use of perampanel in children with refractory epilepsy of genetic aetiology.
    Qu R; Dai Y; Qu X; Li Y; Shao X; Zhou R; Zhu Y; Chen X
    Epileptic Disord; 2022 Aug; 24(4):687-695. PubMed ID: 35770768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of perampanel in young children with drug-resistant epilepsy.
    Chang FM; Fan PC; Weng WC; Chang CH; Lee WT
    Seizure; 2020 Feb; 75():82-86. PubMed ID: 31901668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study.
    Delanty N; Mohanraj R; Shankar R; Wehner T; Stephen LJ; D'Souza W; Cappucci S; McMurray R; Sainz-Fuertes R; Villanueva V
    Epilepsy Res; 2024 May; 202():107339. PubMed ID: 38492461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study.
    Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T
    Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
    Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
    Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study.
    Qu R; Dai Y; Chen X; Li R; Liu M; Zhu Y
    Epileptic Disord; 2021 Dec; 23(6):854-864. PubMed ID: 34730518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and efficacy of perampanel in children with refractory epilepsy.
    Heyman E; Lahat E; Levin N; Epstein O; Lazinger M; Berkovitch M; Gandelman-Marton R
    Dev Med Child Neurol; 2017 Apr; 59(4):441-444. PubMed ID: 27935018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
    Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
    Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
    Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
    Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
    Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
    Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WRAPPER study: Real-world effectiveness and tolerability of adjunctive perampanel for people with drug-resistant epilepsy in Hong Kong.
    Chan CCH; Leung HW
    Epilepsia Open; 2024 Feb; 9(1):345-354. PubMed ID: 38101856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of adjunctive perampanel in pediatric patients (aged 4-12 years) with refractory epilepsy: An observational study.
    Chu SJ; Li Y; Tang JH
    Medicine (Baltimore); 2022 Nov; 101(45):e31408. PubMed ID: 36397377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.